Inhibrx Biosciences, INC Form 4 insider transactions

Kristiina Vuori, a director at Inhibrx Biosciences, recently purchased additional shares of the company's common stock, increasing her beneficial ownership.

Inhibrx Biosciences CEO Mark Lappe reports purchasing additional shares of the company's common stock through the Lappe Family Trust.

Inhibrx Biosciences CEO Mark Lappe has been actively purchasing company stock through personal and trust accounts, increasing his beneficial ownership.

Kristiina Vuori, a director of Inhibrx Biosciences, purchased 7,140 shares of common stock at $14 per share on August 29, 2024.

Director Kimberly Manhard purchased 10,000 shares of Inhibrx Biosciences (INBX) at an average price of $13.98 on August 28, 2024.

Director Douglas Forsyth has increased his indirect holdings in Inhibrx Biosciences through purchases made via the Forsyth Family Trust.

Inhibrx Biosciences CEO Mark Lappe recently purchased additional shares of the company's common stock through indirect holdings.

Director Jon Faiz Kayyem of Inhibrx Biosciences reports gifting shares of common stock to family members and trusts, with no monetary transaction involved.

Director Jon Faiz Kayyem reports purchasing additional shares of Inhibrx Biosciences, Inc. through a family trust.

Director Jon Faiz Kayyem reports multiple purchases of Inhibrx Biosciences (INBX) common stock, increasing his indirect holdings through a family trust.

Inhibrx, Inc. reports a distribution of Inhibrx Biosciences, Inc. common stock to its shareholders, resulting in changes in beneficial ownership.

Kristiina Vuori, a director at Inhibrx Biosciences, acquired stock options for 30,000 shares of common stock following the merger with a Sanofi subsidiary.

Director Kimberly Manhard received stock options for 30,000 shares of Inhibrx Biosciences common stock following the merger with a Sanofi subsidiary.

Following the distribution of Inhibrx Biosciences shares and a merger with Sanofi, CEO Mark Lappe reports acquiring shares through trusts and receiving a stock option grant.

Director Jon Faiz Kayyem reports acquiring shares and stock options in Inhibrx Biosciences following the distribution of shares related to the merger with Sanofi.

Director Douglas Forsyth acquires 149,564 shares of Inhibrx Biosciences due to the distribution of shares from Inhibrx, Inc. and receives a stock option for 30,000 shares.

Chief Scientific Officer Brendan P. Eckelman reports acquisition of Inhibrx Biosciences shares and stock options following the distribution of shares related to the Sanofi merger.

Following the merger of Inhibrx, Inc. with a Sanofi subsidiary, CFO Kelly Deck received stock options for 175,000 shares.